Figure 7.

Depletion of CD4⁺ T cells abrogated the enhanced efficacy of the combination therapy

The experimental designs are presented in Figure S4. (A and B) Tumor growth (A) and survival analysis (B) of CD8⁺ T cell depletion assay (n = 7). A CD8⁺ T cell depletion decreased but did not abolish the enhanced efficacy of the combination therapy (0/7 cures). (C and D) Tumor growth (C) and survival analysis (D) of CD4⁺ T cell depletion assay (n = 7). The efficacy of the combination therapy was completely abrogated by a depletion of CD4⁺ T cells. (E and F) Tumor growth (E) and survival analysis (F) of the NK cell depletion assay (n = 7). The synergistic therapeutic effect and the survival benefit by the combination therapy were retained under a depletion of NK cells (1/7 cure). The results are presented as the mean ± SEM. One-way ANOVA followed by Dunnett’s test was used for comparisons of tumor growth. For the survival analysis, the log-rank test followed by Holm’s sequential Bonferroni corrections was used to determine statistical significance (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant).